Business Standard

GSK Pharma: Near term headwinds may keep stock prices under pressure

April sales were the worst among top drug players

GSK, PHARMA, GLAXO
Premium

The uncertainty on the divestment of its Vemgal plant in Karnataka is another trigger for the stock.

Ram Prasad Sahu
The GlaxoSmithKline Pharma (GSK Pharma) stock has dipped 7 per cent from its May highs, on worries that lower incidence of acute infections could lead to a fall in sales. Some brokerages have downgraded the stock due to a weak near-term outlook. 

Vinay Bafna and Sriraam Rathi of ICICI Securities have reduced their net profit estimates for FY21 and FY22 by 12-14 per cent, factoring in the near-term pressure caused by Covid-19, adoption of a healthier lifestyle, and social distancing that will affect acute therapy sales.  

Worries on the acute therapy front arise from the April show. GSK was the

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in